

---

## Product Data Sheet

---

Product Name: AZ7550 Mesylate (AZ7550 trimesylate salt)

Cat. No.: GC34414

### Chemical Properties

Cas. No.

SMILES CN1C=C(C2=NC(NC3=CC(NC(C=C)=O)=C(N(CCNC)C)C=C3OC)=NC=C2)C4=CC=CC=C41.O=S(O)(C)=O.O=S(O)(C)=O.O=S(O)(C)=O

Formula C<sub>30</sub>H<sub>43</sub>N<sub>7</sub>O<sub>11</sub>S<sub>3</sub>

M.Wt

773.9

Solubility DMSO : 4.18 mg/mL (5.40 mM)

Storage

Store at -20°C

General For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic tips bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice Condition upon request.

Structure

### Protocol

#### Kinase experiment:

Biochemical enzyme profiling of AZD9291 and active metabolites across the kinome panel (single profiling experiment representative of two independent studies). % inhibition for kinases in the ~280 kinase panel that shows greater than 60% inhibition after 1 μM treatment with AZD9291, AZ5104 or AZ7550, and follow-up IC50s where tested, are shown. Kinases with a conserved cysteine in the analogous position within their catalytic domain as Cys797 in EGFR are also shown, highlighted in bold[1].

References:

[1]. Finlay MR, et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem. 2014 Oct 23;57(20):8249-67.

### Background

AZ 7550 is an active metabolite of AZ 9291 <sup>1</sup>. It inhibits the insulin-like growth factor 1 receptor (IGF-1R) in a

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

cell-free assay ( $IC_{50} = 1.6 \mu M$ ). It inhibits EGFR autophosphorylation in H1975 and PC-9 cells expressing the respective constitutively active mutants EGFR<sup>T790M/L858R</sup> and EGFR<sup>Exon19del</sup> ( $IC_{50}$ s = 0.045 and 0.026  $\mu M$ , respectively), as well as in LoVo cells expressing wild-type EGFR ( $IC_{50} = 0.786 \mu M$ ).

1. Finlay, M.R., Anderton, M., Ashton, S., et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. *J. Med. Chem.* 57(20):8249-8267(2014)

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---